Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribociclib vs Chemotherapy in Aggressive Advanced Breast Cancer (RIGHT Choice)
NCT03839823Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2019
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 2, randomised, open-label trial of ribociclib in breast cancer (2 arms), sponsored by Novartis. Primary endpoint: Progression-free Survival at 34 months. Started Feb 2019; status: completed.
02
Drugs
ribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03839823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03839823.